Beyaz/Safyral drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium regulatory update

Bayer updated the labels for its drospirenone-containing oral contraceptives to include additional information on the risk for venous thromboembolism (VTE). Specifically, the label notes combination oral contraceptive containing drospirenone may be associated with a higher risk of VTE than those containing levonorgestrel or some other progestins. Marketed drospirenone-containing contraceptives include Bayer's Beyaz/Safyral drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets and Yaz/Yasmin drospirenone/ethinyl estradiol tablets. Drospirenone-containing contraceptives are available as generics. ...